ReviewDiscover oncology2023
Chemotherapy-induced thrombocytopenia: literature review.
Review in Discover oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07586813 (A Prospective, Randomized, Open-Label, Controlled Study of Romiplostim N01 Combined With All-Trans Retinoic Acid Versus Romiplostim N01 Alone for Persistent Isolated Chemotherapy-Induced Thrombocytopenia in Patients With Complete Remission of Gastrointestinal Solid Tumors), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Randomized, Open-Label, Controlled Study of Romiplostim N01 Combined With All-Trans Retinoic Acid Versus Romiplostim N01 Alone for Persistent Isolated Chemotherapy-Induced Thrombocytopenia in Patients With Complete Remission of Gastrointestinal Solid Tumors
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025Pooled it
- Hematologic Toxicities and Determinants Among Patients With Breast Cancer Treated With Doxorubicin-Cyclophosphamide Followed by Paclitaxel in Northwest Ethiopia: A Retrospective Cohort Study.Health science reports · 2026Article
- Article
- Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.Blood science (Baltimore, Md.) · 2026Article
- Efficacy and clinical outcomes of proximal splenic artery embolization in patients with chemotherapy induced thrombocytopenia.Langenbeck's archives of surgery · 2026Article
- Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer.British journal of cancer · 2026Article
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
- The Plasma Glycoprotein Milieu in the Hemato-Oncological Patient Inhibits Platelet Function.Biomolecules · 2026Article
- Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer.Breast (Edinburgh, Scotland) · 2026Review
- Avatrombopag Reduces Platelet Transfusion Requirement in Thrombocytopenia Subsequent to Antineoplastic Therapies in Haematological Patients: The Experience of a Tertiary Centre.Journal of clinical medicine · 2026Article
- Balancing Thrombosis and Bleeding: Antithrombotic Therapy in Cirrhosis-Related Thrombocytopenia.Journal of clinical medicine · 2026Review
- Population PK/PD Modeling for Evaluation of Intertwining Effects of Drug and Disease on Thrombocytopenia in Acute Leukemias.CPT: pharmacometrics & systems pharmacology · 2026Article
- Response to: comment on "Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma".Hepatology international · 2026Article
- Avatrombopag switching from other thrombopoietic agents in severe and persistent cancer treatment-induced thrombocytopenia: a multicentre real-world study.Frontiers in medicine · 2026Article
- A novel prognostic model integrating host vulnerability and tumor biology for elderly patients with diffuse large B-cell lymphoma: the BAMAL score.Frontiers in oncology · 2026Article
- Recurrent severe thrombocytopenia induced by anti-HER2 therapy in a breast cancer patient with an underlying immune disorder: a case report and literature review.Frontiers in oncology · 2026Article
- Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.Research and practice in thrombosis and haemostasis · 2026Review
- Machine learning-based models for predicting the efficacy and safety of recombinant human interleukin-11 in the treatment of cancer therapy-induced thrombocytopenia: exploration and preliminary validation from a multicenter retrospective study.Frontiers in cell and developmental biology · 2026Article
- Impact of prior solid tumor on outcomes of hematopoietic stem cell transplantation for hematologic malignancies: a propensity score-matched study.Frontiers in immunology · 2026Article
- Case Report: Prolonged thrombocytopenia after chemotherapy in solid tumors requiring long-term thrombopoietin receptor agonist support: a five-patient case series.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chemotherapy-induced thrombocytopenia (CIT) is a common condition that frequently results in reduced chemotherapy dosages, postponed treatment, bleeding, and unfavorable oncological outcomes. At present, there is no clear suggestions for preventing or treating CIT. Thrombopoietin (TPO) replacement therapy has been invented and used to treat CIT to promote the production of megakaryocytes and stimulate the formation of platelets. However, this treatment is limited to the risk of immunogenicity and cancer progression. Therefore, an unmet need exists for exploring alternatives to TPO to address the clinical issue of CIT. Application of appropriate therapeutic drugs may be due to understanding the potential mechanisms of CIT. Studies have shown that chemotherapy significantly affects various cells in bone marrow (BM) microenvironment, reduces their ability to support normal hematopoiesis, and may lead to BM damage, including CIT in cancer patients. This review focuses on the epidemiology and treatment of cancer patients with CIT. We also introduce some recent progress to understand the cellular and molecular mechanisms of chemotherapy inhibiting normal hematopoiesis and causing thrombocytopenia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.